

Age at natural menopause and life expectancy with and without type 2 diabetes.

Menopausal age, life expectancy and diabetes.

Eralda Asllanaj MD, MSc, DSc^{1,2}, Arjola Bano MD, MSc, DSc^{1,3}, Marija Glisic MD, MSc¹, Loes Jaspers MD, PhD¹, M. Arfan Ikram MD, PhD^{1,4}, Joop S.E. Laven MD, PhD⁵, Henry Völzke MD, PhD^{2,6,7}, Taulant Muka MD, PhD¹, Oscar H. Franco MD, PhD^{1,8}

¹ Department of Epidemiology, Erasmus University Medical Center, The Netherlands.

² Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany

³ Department of Internal Medicine, Section Pharmacology Vascular and Metabolic diseases, Erasmus University Medical Center, Rotterdam, The Netherlands

⁴ Department of Neurology, Erasmus University Medical Center, The Netherlands

⁵ Department of Obstetrics and Gynaecology, Erasmus University Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands

⁶ DZHK (German Center for Cardiovascular Research), partner site Greifswald, Greifswald, Germany

⁷ German Center for Diabetes Research, Partner Site Greifswald, Germany

⁸ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

- 17 Corresponding author: Eralda Asllanaj, MD, MSc, Department of Epidemiology, Erasmus University Medical Center, Dr.
18 Molewaterplein 50, Office NA29-11, PO Box 2040, 3000 CA Rotterdam, the Netherlands. Tel: +31 10 7038910. Email:
19 e.asllanaj@erasmusmc.nl
- 20 **Funding/Support:** Nothing to declare
- 21 **Conflict of interest/financial disclosure:** Nothing to declare

22 Word count

23 Abstract: 215 words; Text: 4040 words

24

25 **ABSTRACT**

26 **Objective:** Effective interventions of future health-care require a better understanding of the health risks associated with early onset of
27 menopause and diabetes, but the necessary data are scarce. Little quantitative information is available about the combined association
28 of early menopause and diabetes on life expectancy and the number of years lived with and without diabetes.

29 **Methods:** We included 3,650 postmenopausal women aged 45+ years from the Rotterdam Study, a prospective population-based
30 cohort study. Age at menopause categories were defined as: early (≤ 44 years old), normal (45-54 years old) and late (≥ 55 years old).
31 For life table calculations, we used prevalence, incidence rates and hazard ratios for three transitions (free of diabetes to diabetes, free
32 of diabetes to death and diabetes to death) stratifying by age at menopause categories and adjusting for confounders.

33 **Results:** Compared to late menopause, the difference in life expectancy for women who experienced early menopause was -3.5
34 95%CI: -6.6,-0.8 years overall and -4.6 95%CI: -8.9,-0.9 years without diabetes. Compared to age at normal menopause, the
35 difference in life expectancy for women who experienced early menopause was -3.1 95%CI: -5.1,-1.1 years overall and -3.3 95%CI: -
36 6.0,-0.6 years without diabetes.

37 **Conclusions:** Women who experienced early menopause lived less long and spent fewer years without diabetes than women who
38 experienced normal or late menopause.

39 **Keywords:** Age at menopause; life expectancy; type 2 diabetes

40 **ABBREVIATIONS**

41 T2D, Type 2 diabetes

42 RS, The Rotterdam Study

43 LE, Life expectancy

44 HR, Hazard Ratio

45 CI, Confidence Interval

46 IQR, Interquartile range

47 SD, Standard deviation

48 VIF, Variance inflation factor

49 INTRODUCTION

50 Diabetes is one of the major causes of premature illness and death in most countries and imposes a substantial financial burden to
51 society, especially in women [1, 2]. Almost 1 in 2 women will develop type 2 diabetes (T2D) during their lifetime, and recent data has
52 shown that the age-standardised prevalence of diabetes among adult women has increased in the past 30 years from 5.0% to 7.9% [3,
53 4].

54 In women, T2D often manifests during mid-life and thus coincides with the timing of the menopausal transition [5]. Emerging
55 evidence shows an association between age at menopause and diabetes with studies reporting almost a 2-fold increased risk of T2D
56 with early onset of menopause [6, 7]. Also, it is well established that early onset of menopause is associated with early death[8-10].
57 This could be important because, while mortality rates for women with non-T2D have declined over time [11], mortality rates for
58 women with T2D may have instead increased [11].

59 Effective interventions and accurate projections of future health-care costs require a better understanding of the health risks associated
60 with early onset of menopause, but the relevant data are scarce. To our knowledge, no study up to date has quantified (calculating the
61 number of years lived with and without diabetes) the combined association of early menopause and T2D with life expectancy.

62 Previous estimates reflecting the association of age at menopause with diabetes have been limited to absolute risks or lifetime risk
63 without combining information about the number of the remaining years lived with or without diabetes, raising a gap in the intuitive
64 understanding of risk and impact communicated among doctors and patients [6, 7, 12].

Two studies have examined the association of age at menopause with total life expectancy [13, 14]. Ossewaarde and colleagues, in a breast cancer-screening cohort, reported that both premature and early onset of menopause were associated with a decrease in life expectancy of approximately 1 to 2 years [13]. Snowdon et al. concluded that each-one year decrease in age at menopause was associated with a 0.47-year decrease in the age at death in women with natural menopause before the age of 47 years [14]. However, these studies did not distinguish between life expectancy with and without diabetes and did not provide a direct observation of a well-defined population, as the results were obtained through modelling and simulation using nation-wide mortality data.

In a large population of postmenopausal women, we aimed to calculate and compare the association of age at natural menopause with total life expectancy and the number of years lived with and without T2D.

METHODS

Population for analyses

The Rotterdam Study (RS) is a population-based prospective cohort study of individuals aged 45 years and over, living in Rotterdam, the Netherlands. The rationale and design of the RS have been previously described [15].

The present study used data from the third visit of the first cohort, RSI-3 (March 1997- December 1999) and the baseline examinations of the second, RSII-1 (February 2000-December 2001) and third cohort, RSIII-1 (February 2006-December 2008). Information about the visits and participants used for this study are presented in Supplemental Digital Content Figure S1. A total of 6816 women were

eligible for the analysis. Women who were not postmenopausal (N=741), had missing information on age of menopause (N=145), experienced non-natural (N=1408) or unknown type of menopause (N=20) were excluded from the analyses. Furthermore, we excluded 434 women who reported using oral contraceptives during the menopause transition, since these may mask or influence the onset of menopause [16] and are associated with an increased risk of T2D in postmenopausal women [17]. The remaining 3650 postmenopausal women were eligible for the analyses (Figure 1).

Study population

The Rotterdam Study (RS) is a population-based prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. Potential participants aged 55 years and over were invited in random clusters. Names and addresses were drawn from the municipal register which is reliable, complete and up to date. The baseline cohort (RSI) included 7983 participants (78% of 10,215 invitees)[18]. Over the years, two more rounds were held. The first, in 2000–2001, included all inhabitants aged 55 years and over, recruiting 3011 participants (out of 4472 invitees) (RSII)[18]. The second extension initiated in 2006, included 3932 participants aged 45 years and over, out of 6057 invited (RSIII)[18]. Detailed information about the visits and participants of the Rotterdam study are presented in Supplemental Digital Content Figure S1. The overall response figure for all three cycles was 72.0% (14,926 of 20,744). RS complies with the Declaration of Helsinki and has been approved by the Medical Ethics Committee of the Erasmus Medical Centre and complies with the Dutch Ministry of Health, Welfare and Sport. All participants provided written informed consent to obtain and process data from their treating healthcare providers.

97 **Assessment of age at menopause**

98 The self-reported age at menopause was assessed during the baseline interview using a questionnaire. Age at menopause was defined
99 in retrospect as the age at final menstrual period, which was followed by cessation of menses that lasted at least 12 months [19]. In
100 addition, to define the nature of menopause, women were asked to report if bleeding was ceased naturally or was ceased because of
101 other reason. For all women reporting menopause after gynecologic surgery or radiation therapy and for those reporting any other
102 operations that might have led to menopause, information on the exact date and type of operation was verified using general
103 practitioners' records.

104 **Ascertainment of type 2 diabetes**

105 The participants were followed from the date of baseline center visit onwards. Cases of T2D were ascertained at baseline and during
106 follow-up through: (i) active follow-up using general practitioners' records, (ii) hospital discharge letters and (iii) glucose
107 measurements from RS visits that took place approximately every 4 years [20]. T2D was defined according to recent WHO guidelines,
108 as a fasting blood glucose ≥ 7.0 mmol/L, a non-fasting blood glucose ≥ 11.1 mmol/L (when fasting samples were absent), or the use of
109 glucose-lowering medication. Information regarding the use of glucose-lowering medication was derived from both structured home
110 interviews and linkage to pharmacy records [20]. Two study physicians independently adjudicated all potential events of T2D. In case
111 of disagreement, consensus was sought with an endocrinologist. Follow-up data were through January 1st 2012.

112 **Follow-up for mortality**

113 Mortality data were obtained by notification from the municipal administration. Participants were followed from the first day they
114 entered the study till the day of death, the day of lost to follow-up or the last date of contact, whichever came first. Data on all-cause
115 mortality and living status were updated biweekly until August 1st 2016. The method applied requires all outcomes to have the same
116 end date. In our data, the follow up for diabetes was until January 1st 2012, therefore all the analyses were truncated accordingly.

117 **Assessment of potential confounders**

118 Based on previous literature[7, 10, 16, 17, 21-24], biological plausibility and data availability in the RS, potential confounding
119 variables (including age, smoking, alcohol, education level, hormone therapy, physical activity, age at menarche, number of
120 pregnancies and oral contraceptive use) were selected for the analyses. Also, to account for any potential effect of the cohorts in the
121 RS, we additionally adjusted all our analyses for cohort (I, II and III). Information on current health status, medical history, medication
122 use and smoking behavior was obtained at baseline (RSI-3, RSII-1 and RSIII-1). Participants were asked whether they were currently
123 smoking cigarettes, cigars, or pipes. Alcohol intake was assessed in grams of ethanol per day. Education was defined according to the
124 standard international classification of education as low (primary education), intermediate (secondary general or vocational
125 education), or high (higher vocational education or university). Data on age at menarche were collected by asking women, “How old
126 were you when you had your first menstrual period?”. The retrospective data on self-reported number of pregnancies and use of
127 hormone therapy were collected by a questionnaire during the home interview. Physical activity was assessed using the LASA
128 Physical Activity Questionnaire (LAPAQ) and is expressed in METhours/week.

129 **Data analysis**

130 Data are presented as mean (\pm SD) for normally distributed continuous variables and median (range) for continuous variables that are
131 not normally distributed. When fitting the models and checking for multicollinearity, in our analyses variance inflation factor (VIF)
132 was lower than 3, suggesting no evidence of collinearity. The One-way ANOVA test (for continuous variables) and χ^2 (for
133 categorical variables) were used to compare parameters between the groups. We created population-based multistate life tables to
134 calculate life expectancy and years lived with and without T2D in early (≤ 44 years old), normal (45-54 years old) and late menopause
135 (≥ 55 years old, reference) categories. The multistate life table is a demographic tool that allows the experience of individuals in
136 different health states to be combined in order to calculate the total life expectancy and the amount of years that individuals could
137 expect to live in the different health states. We considered 3 different health states: free of T2D, T2D, and death. Participants could
138 experience the following transitions: from free of T2D to T2D or death and from T2D to death. No backflows were allowed (eg. from
139 having T2D to not having T2D), and only the first entry into a state was considered.

140 To obtain transition rates, we first calculated the overall age-specific rates for each transition. Next, we calculated the prevalence of
141 early, normal, and late menopause by 10-year age groups, and separately for women with and without diabetes. Hazard ratios (HRs)
142 comparing women who experienced early and normal menopause to women who experienced late menopause were calculated using
143 Poisson regression (“Gompertz” distribution) in two models. In model 1 we adjusted for age and cohort. In model 2 we additionally
144 adjusted for potential confounders including: smoking status (current smokers vs former/ever smokers), alcohol intake (continuous),

education level (low, intermediate and high), physical activity (continuous), use of oral contraceptives (yes vs. no), use of hormone therapy, and reproductive factors (age at menarche and number of pregnancies of at least 6 months). Finally, we calculated three sets of transition rates for each menopausal age category using (i) the overall transition rates, (ii) the adjusted HRs for T2D and mortality, and (iii) the prevalence of age at natural menopause categories by presence of T2D. Similar calculations have been described previously [25, 26]. Considering the age range of participants in RS and the small number of participants between 45 to 50 years old (N=34) we a priori decided to start the multistate life tables at the age of 50 years. We used Monte Carlo simulation (parametric bootstrapping) with 10,000 runs to calculate the 95 % confidence intervals of our life expectancy estimates with @RISK software (Palisade Corporation, Ithaca, New York) runs [27]. To deal with missing values, we used multiple imputation in SPSS (IBM SPSS Statistical for Windows, Armonk, New York: IBM). To calculate the HRs and the transition rates we used STATA version 12 for Windows (StataCorp, College Station, Texas).

Sensitivity analyses

Several sensitivity analyses were performed. To examine the impact of women who reported use of oral contraceptive at onset of menopause, we included them in the analyses (n=434). Also, to investigate both, the association of natural and non-natural menopause with T2D risk and life expectancy, we included in the analyses women with non-natural menopause. Furthermore, to explore whether there were significant differences between early and normal age at menopause in risk of T2D and mortality, life expectancy, and years lived with and without T2D, we repeated the analysis using normal age at menopause category as reference.

161 **RESULTS**

162 **Baseline characteristics**

163 Mean age at menopause in the early, normal and late categories were respectively 41 years (SD = 3.0), 50 years (SD=2.5) and 56 years
164 (SD=1.6) (Table 1). Compared to women who experienced late menopause, early menopausal women had lower education levels,
165 drank less and were more likely to smoke (Table 1).

166 **Diabetes events and death**

167 Of the 3240 postmenopausal women free of diabetes at baseline, 305 women developed incident T2D over a median follow-up of 9.2
168 years (Table 2). Among women free of diabetes, 489 women died during the follow-up (median= 6.9 years), whereas 164 women died
169 among women with T2D (median follow-up= 4.9 years). Both models yielded similar estimates; therefore, we further report the
170 results of the most adjusted model (model 2). Compared to late menopause, early (HR=1.42, 95% CI: 1.01, 2.00), but not age at
171 normal menopause (HR=1.13, 95% CI: 0.85, 1.49) was associated with an increased risk of mortality among women free of diabetes.
172 Among diabetic women with early and normal menopause, the HRs for mortality were 1.64 95% CI: 0.93, 2.88, and 0.85 95% CI:
173 0.52, 1.39 respectively, relative to those with late menopause (Table 2).

174 **Total life expectancy and life expectancy with and without type 2 diabetes.**

175 The association of early, normal, and late menopause with the risk of each health/disease/death transition was translated into the
 176 number of years lived with and without diabetes (Figure 2). Total life expectancy at the age of 50 years was lower in women who had
 177 an early menopause and higher in women who had a late menopause. Compared to women with late menopause, the difference in life
 178 expectancy for women with normal and early age at menopause was 0.5 95% CI: -2.1, 1.3 and 3.5 95% CI: -6.6,-0.8 years,
 179 respectively. Compared to women with late menopause, the difference in life expectancy for women with normal and early age at
 180 menopause was 1.3 95% CI: -4.3, 0.8 and 4.6 95% CI: -8.9,-0.9 years without T2D as well as 0.8 years 95% CI: -1.3, 2.4 and 1.1 years
 181 95% CI: -1.8, 4.4 years with T2D, respectively.

182 **Sensitivity analyses**

183 Total life expectancy and the number of years lived with and without T2D did not significantly differ after including women who
 184 reported using oral contraceptives. These results are presented in Supplemental Digital Content Table S1, Table S2, Figure S2. The
 185 results were attenuated, but did not substantially change after the inclusion of women with non-natural menopause (results are shown
 186 in Supplemental Digital Content Table S3, Table S4 and Figure S3). Furthermore, the difference in life expectancy for women who
 187 experienced early menopause, compared to women with normal age at menopause was -3.1 95% CI: -5.1,-1.1) and -3.3 95% CI: -9.5,
 188 -0.6 years overall and without T2D respectively, and 0.2 95% CI: -2.0,2.8 years with T2D, although the latter was not a statistically
 189 significant difference. Results using the normal menopause group as the reference category are presented in Supplemental Digital
 190 Content Figure S2, Table S5 and S6.

191 **DISCUSSION**

192 At the age of 50 years, women who experienced early menopause lived less years and spent fewer years without diabetes than women
193 who experienced normal or late menopause. Compared to women with normal or late age at menopause, women with early
194 menopause lived at least 3.1 years fewer overall and at least 3.3 years fewer without diabetes, respectively.

195 The decreased life expectancy without diabetes among women with early menopause might be due to the increased risk of T2D and
196 mortality associated with early menopause. The higher risk of diabetes in women with early age at natural menopause might reflect an
197 earlier diagnosis of diabetes across the lifespan and therefore, a decreased life expectancy without T2D, although the difference in
198 years lived overall and without T2D did not differ significantly. Furthermore, early menopause was also associated with an increased
199 mortality risk among participants without T2D, resulting in a further decrease in total life expectancy and number of years lived
200 without T2D. The number of years lived with diabetes was a result of incident diabetes risk and mortality risk among those with
201 diabetes. In our study, no significant association was observed of age at menopause with mortality among women with diabetes, which
202 could be due to the small number of cases in this transition (transition 3). Life expectancy with diabetes was at least 0.2 and 1.1 years
203 more for women with early age at menopause compared with those who experienced normal and late menopause respectively. This
204 reflects two opposing results: 1) higher incidence of diabetes in women who experienced early menopause increasing the time spent
205 with diabetes; and 2) increased mortality associated with early menopause in diabetic patients, decreasing the time spent with diabetes.
206 The net result is that women who experienced early menopause lived shorter and did not spend more years with diabetes.

207 In our study, total life expectancy in women aged 50 years and over was very similar between normal and late menopause and
 208 significantly decreased in the early menopause group. Consistent with our findings, data from a breast cancer screening cohort
 209 reported that a later menopause is associated with a longer overall survival and higher life expectancy [13]. In that study, women who
 210 experienced menopause at the age of 55 years or after lived 2 and 1 years longer than those who experienced menopause before the
 211 age of 40 and at age 40-44 respectively, which is slightly less than our findings. This discrepancy could be explained by differences in:
 212 (i) age of participants; (ii) categorization of age at menopause and (iii) in the calendar time of baseline measurements. Also, our study
 213 included only women who experienced natural menopause, whereas the previous study included women experiencing natural and not-
 214 natural menopause. Furthermore, in the previous study, the calculations for the life tables were made using a hypothetical population
 215 of women aged 50 years, obtaining estimates by modelling and simulation. In contrast, our study calculated the life expectancy with
 216 and without diabetes from direct observation of a well-defined population using multistate life tables.

217 Previous studies have reported that among major modifiable risk factors, never smoking was associated with the largest gain in total
 218 life expectancy in women (up to 4.1 years), followed by high physical activity (3.4 years) and normal weight (1.0 year) [28]. In our
 219 study, adjustment for these factors to rule out their influence on the association between age at menopause and T2D did not materially
 220 change the results. Previous studies investigating the association of age at menopause and mortality or diabetes, have also reported no
 221 changes in estimates when adjusting for smoking [7, 13], suggesting that smoking habits could not explain our findings. However, it
 222 would be of interest to explore whether smoking and early menopause are related through epigenetic mechanisms which can further
 223 affect women's health later in life.

224 To our knowledge, this is the first study that investigated the association of age at natural menopause with life expectancy with and
225 without T2D. Other major strengths include the prospective design with a long-term follow-up; the large number of participants and
226 the adjustments for a broad range of potential confounders.

227 Several limitations of this study should be addressed. Age at menopause was assessed by questionnaires that could be subject to some
228 measurement error. Another limitation was the reliance on retrospective self-report of age at menopause that could be subject to
229 memory and reporting bias, particularly in older women. In addition, inaccuracy from reporting bias would have been non-differential
230 in relation to the menopausal categories. Hence, it is unlikely that this would have created any difference between groups. However,
231 because T2D and mortality were assessed prospectively, the subjective measure of age at menopause would likely lead to non-
232 differential misclassification with respect to the outcome, and therefore would likely bias our estimates toward the null. Furthermore,
233 studies have reported that the validity and reproducibility of self-reported age at menopause is fairly good [8, 29].

234 Moreover, diabetes might have been subclinical at baseline and because age at menopause was retrospectively self-reported, the
235 possibility of reverse causality should be considered. However, all women in our study were already postmenopausal years before
236 incident diabetes occurred. Also, all women in RS had an assessment of fasting plasma glucose which would have helped to detect
237 subclinical diabetes and therefore reverse causality is less likely to have happened.

238 Further, a time difference was observed between the start of the RS and the onset of menopause, which might have introduced
239 immortal-time bias. Nevertheless, if immortal-time bias was present, the true point estimate for the relationship between early

240 menopause, T2D and mortality may be larger than we observed. Also, all population-based cohorts involving active participation are
241 subject to the healthy volunteer effect [30] therefore the mortality rates in our study might be lower than those in the general
242 population, thus leading to underestimation of the results [31]. Finally, the generalizability of our findings can be limited to middle-
243 aged and older white European populations, and therefore, our results need confirmation in other populations.

244 These results support findings of prior studies that suggest that age at natural menopause might be a risk factor for mortality. Another
245 hypothesis might be that both early menopause and premature death could be associated by a third factor, which may also partly
246 explain the underlying mechanisms of the greater risk of T2D in women with early menopause. Epigenetic modifications such as
247 DNA methylation of cytosine residues in CpG dinucleotides histone modification and micro RNAs might constitute an additional
248 pathway linking the timing when menopause occurs with longevity and type 2 diabetes [32]. Future studies should explore epigenetic
249 modifications associated with age at natural menopause and whether epigenetic signatures can explain the association between the
250 onset of natural menopause with mortality and type 2 diabetes risk. In addition, our results provide supporting evidence for public
251 health interventions aiming at delaying in menopause to reduce the incidence of T2D, postpone mortality and prolong total life
252 expectancy as well as the years lived free of diabetes. Studies have shown that various lifestyle factors [22] such as smoking cessation
253 [23, 33], low to moderate alcohol consumption [23], better nutrition and lower body mass index [21, 34], better socioeconomic status
254 [22], are associated with a later menopause. Considering the observational nature of the studies so far, it is unclear whether these
255 factors have a causal effect on age of menopause. Therefore, more research is needed to understand the direction of these associations

256 to help define better health policies. Also, our findings might be important for the health care sector since diabetes poses a significant
257 financial burden on healthcare and nations' welfare budget [35].

258 CONCLUSIONS

259 In our study, women who experienced early menopause lived fewer years overall and spent less years without diabetes than women
260 who experienced normal or late menopause. Future studies are needed to examine the mechanisms behind the association of age at
261 natural menopause with type 2 diabetes and mortality, in order to tailor prevention and treatment strategies to improve women's health
262 across all age-categories of menopause.

263 **Author's contribution:**

264 **Study concept and design:** TM and OHF

265 Acquisition, collection, analysis, or interpretation of data: EA, AB, MG, LJ, MAF, JSEL, HV, TM, OHF

266 Drafting of the manuscript: EA, TM

267 Critical revision of the manuscript for important intellectual content: AB, MG, LJ, MAF, JSEL, HV, TM, OHF

268 Statistical analyses: EA

269 Study supervision: TM, OHF

270 All authors approved the final version of the manuscript.

271

272 REFERENCES

- 273 1. Williams, J.S., et al., *Sex differences in healthcare expenditures among adults with diabetes: evidence from the medical expenditure panel*
274 *survey, 2002-2011*. BMC Health Services Research, 2017.
- 275 2. Zhuo, X.H., et al., *The Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention*. *Diabetes Care*, 2014. **37**(9): p. 2557-2564.
- 276 3. Narayan, K.M., et al., *Lifetime risk for diabetes mellitus in the United States*. *JAMA*, 2003. **290**(14): p. 1884-90.
- 277 4. Zhou, B., et al., *Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants*.
278 *Lancet*, 2016. **387**(10027): p. 1513-1530.
- 279 5. Karvonen-Gutierrez, C.A., S.K. Park, and C. Kim, *Diabetes and Menopause*. *Curr Diab Rep*, 2016. **16**(4): p. 20.
- 280 6. Brand, J.S., et al., *Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study*. *Diabetes Care*,
281 2013. **36**(4): p. 1012-9.
- 282 7. Muka, T., et al., *Age at natural menopause and risk of type 2 diabetes: a prospective cohort study*. *Diabetologia*, 2017. **60**(10): p. 1951-
283 1960.
- 284 8. Muka, T., et al., *Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes,*
285 *Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis*. *JAMA Cardiol*, 2016. **1**(7): p. 767-776.
- 286 9. Jacobsen, B.K., S.F. Knutsen, and G.E. Fraser, *Age at natural menopause and total mortality and mortality from ischemic heart disease:*
287 *The Adventist health study*. *Journal of Clinical Epidemiology*, 1999. **52**(4): p. 303-307.
- 288 10. Gold, E.B., *The Timing of the Age at Which Natural Menopause Occurs*. *Obstetrics and Gynecology Clinics of North America*, 2011. **38**(3):
289 p. 425-+.
- 290 11. Preis, S.R., et al., *Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus*
291 *in the Framingham Heart Study, 1950 to 2005*. *Circulation*, 2009. **119**(13): p. 1728-U65.
- 292 12. Epstein, R.M., B.S. Alper, and T.E. Quill, *Communicating evidence for participatory decision making*. *JAMA*, 2004. **291**(19): p. 2359-66.
- 293 13. Ossewaarde, M.E., et al., *Age at menopause, cause-specific mortality and total life expectancy*. *Epidemiology*, 2005. **16**(4): p. 556-562.
- 294 14. Snowdon, D.A., *Early natural menopause and the duration of postmenopausal life. Findings from a mathematical model of life*
295 *expectancy*. *J Am Geriatr Soc*, 1990. **38**(4): p. 402-8.
- 296 15. Hofman, A., et al., *The Rotterdam Study: 2016 objectives and design update*. *European Journal of Epidemiology*, 2015. **30**(8): p. 661-708.
- 297 16. de Vries, E., et al., *Oral contraceptive use in relation to age at menopause in the DOM cohort*. *Human Reproduction*, 2001. **16**(8): p. 1657-
298 1662.
- 299 17. Kim, S.W., et al., *Long-term effects of oral contraceptives on the prevalence of diabetes in post-menopausal women: 2007-2012*
300 *KNHANES*. *Endocrine*, 2016. **53**(3): p. 816-822.
- 301 18. Ikram, M.A., et al., *The Rotterdam Study: 2018 update on objectives, design and main results*. *Eur J Epidemiol*, 2017. **32**(9): p. 807-850.
- 302 19. Harlow, S.D., et al., *Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging*
303 *reproductive aging*. *J Clin Endocrinol Metab*, 2012. **97**(4): p. 1159-68.

- 304 20. Leening, M.J., et al., *Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study*. Eur J Epidemiol, 2012. **27**(3):
305 p. 173-85.
- 306 21. Dorjgochoo, T., et al., *Dietary and lifestyle predictors of age at natural menopause and reproductive span in the Shanghai Women's*
307 *Health Study*. Menopause-the Journal of the North American Menopause Society, 2008. **15**(5): p. 924-933.
- 308 22. Hardy, R. and D. Kuh, *Social and environmental conditions across the life course and age at menopause in a British birth cohort study*.
309 Bjog-an International Journal of Obstetrics and Gynaecology, 2005. **112**(3): p. 346-354.
- 310 23. Kinney, A., J. Kline, and B. Levin, *Alcohol, caffeine and smoking in relation to age at menopause*. Maturitas, 2006. **54**(1): p. 27-38.
- 311 24. Olsson, L., et al., *High Levels of Education Are Associated With an Increased Risk of Latent Autoimmune Diabetes in Adults Results from*
312 *the Nord-Trondelag Health Study*. Diabetes Care, 2011. **34**(1): p. 102-107.
- 313 25. Franco, O.H., et al., *Effects of physical activity on life expectancy with cardiovascular disease*. Arch Intern Med, 2005. **165**(20): p. 2355-
314 60.
- 315 26. Franco, O.H., et al., *Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular*
316 *disease*. Arch Intern Med, 2007. **167**(11): p. 1145-51.
- 317 27. Rindskopf, D., *An introduction to the bootstrap - Efron, B, Tibshirani, R.J.* Journal of Educational and Behavioral Statistics, 1997. **22**(2): p.
318 245-245.
- 319 28. Nusselder, W.J., et al., *Living healthier for longer: Comparative effects of three heart-healthy behaviors on life expectancy with and*
320 *without cardiovascular disease*. BMC Public Health, 2009. **9**.
- 321 29. denTonkelaar, I., *Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project*. Maturitas,
322 1997. **27**(2): p. 117-123.
- 323 30. Leening, M.J., et al., *Healthy volunteer effect and cardiovascular risk*. Epidemiology, 2014. **25**(3): p. 470-1.
- 324 31. Pizzi, C., et al., *Sample selection and validity of exposure-disease association estimates in cohort studies*. J Epidemiol Community Health,
325 2011. **65**(5): p. 407-11.
- 326 32. Muka, T., et al., *The role of global and regional DNA methylation and histone modifications in glycemic traits and type 2 diabetes: A*
327 *systematic review*. Nutrition Metabolism and Cardiovascular Diseases, 2016. **26**(7): p. 553-566.
- 328 33. Hayatbakhsh, M.R., et al., *Cigarette smoking and age of menopause: A large prospective study*. Maturitas, 2012. **72**(4): p. 346-352.
- 329 34. Tao, X.Y., et al., *Body mass index and age at natural menopause: a meta-analysis*. Menopause-the Journal of the North American
330 Menopause Society, 2015. **22**(4): p. 469-474.
- 331 35. Muka, T., et al., *The global impact of non-communicable diseases on healthcare spending and national income: a systematic review*. Eur J
332 Epidemiol, 2015. **30**(4): p. 251-77.

333

334

335 FIGURES

336 **Figure 1.** Flow chart of participants in the study, the Rotterdam Study (1997-2012).

337 Abbreviations: RS the Rotterdam Study

338 Figure 1 shows the number of women eligible for the analysis after applying the inclusion and exclusion criteria to enter the study.

339

340 **Figure 2.** Life expectancy at 50 years old among women with late, normal and early menopause.

341 Abbreviations: LE life expectancy; T2D type 2 diabetes

342 In dark grey is depicted life expectancy free of diabetes and in light grey is depicted life expectancy with diabetes.

343 *Results after adjusted for: age, cohort, education levels, alcohol, smoking, age at menarche, hormone therapy, physical activity,
344 number of pregnancies and oral contraceptive use.

345 **Late menopause group is the reference category.

346

347 **List of Supplemental Digital Content**

348 Supplemental Digital Content Figure S1.pdf

349 Supplemental Digital Content Table S1.pdf

350 Supplemental Digital Content Table S2.pdf

351 Supplemental Digital Content Figure S2.pdf

352 Supplemental Digital Content Table S3.pdf

353 Supplemental Digital Content Table S4.pdf

354 Supplemental Digital Content Figure S3.pdf

355 Supplemental Digital Content Table S5.pdf

356 Supplemental Digital Content Table S6.pdf

Figure 1. Flow chart of participants in the study, the Rotterdam Study (1997-2012).




Table 1. Baseline Characteristics of 3,650 Women by Age at Menopause Categories, the Rotterdam Study (1997-2012).

Characteristics	Categories of age at menopause*			P-value
	Early (n= 414)	Normal (n=2787)	Late (n= 449)	
Age, mean (SD), y	69.0 (10.6)	67.4 (9.8)	67.9 (8.6)	0.005
Age at menopause, mean (SD)	40.8 (3.0)	50.2 (2.5)	56.0 (1.6)	<0.001
Type 2 Diabetes, Yes (%)	54 (13.0)	304 (10.9)	52 (11.6)	0.11
Age at menarche, mean (SD)	13.4 (1.9)	13.4 (1.7)	13.6 (2.0)	0.216
Education, No. (%)				<0.001
Primary	97 (23.4)	427 (15.3)	55 (12.2)	
Lower	200 (48.3)	1451 (52.1)	234 (53.2)	
Intermediate	88 (21.3)	622 (22.3)	108 (23.0)	
Higher/university	29 (7.0)	287 (10.3)	52 (11.6)	
Smoking Status, Yes. (%)	119 (28.7)	539 (19.3)	54 (12.0)	<0.001
Alcohol, mean (SD), g/day	8.7 (11.9)	9.5 (12.5)	11.4 (13.6)	0.003
Physical activity (METhours/week)	81.4 (44.4)	85.3 (50.4)	83.5 (43.7)	0.297
Hormone therapy, Yes (%)	9 (2.2)	73 (2.6)	9 (2.0)	0.671
Oral contraceptive use, yes (%)	190 (45.9)	1464 (52.5)	230 (51.2)	0.041
Number of pregnancies, mean (SD)	2.5 (2.3)	2.3 (1.9)	2.3 (1.8)	0.235

*Menopause categories are defined as: Early ≤ 44 years old, Normal 45-54 and Late ≥ 55 years old.

Abbreviations: SD; standard deviation

Table 2. Hazard Ratios by Transition Among Categories of Age at Menopause.*

Transition	No. Of Cases	Person-years	Age at Menopause Categories	HR [†]	95% CI	HR [‡]	95% CI
Incident T2D	28	2612	Late	1.00		1.00	
	234	21826	Normal	1.22	0.84,1.78	1.14	0.78,1.67
	42	3917	Early	1.89	1.20,2.97	1.69	1.07,2.67
No T2D to Death	68	2607	Late	1.00		1.00	
	519	19901	Normal	1.16	0.88,1.54	1.13	0.85,1.49
	97	3719	Early	1.49	1.05,2.09	1.42	1.01,2.00
T2D to Death	28	664	Late	1.00		1.00	
	148	3507	Normal	0.91	0.56,1.48	0.85	0.52,1.39
	44	1043	Early	1.73	0.99,3.00	1.64	0.93,2.88


Abbreviations: HR, Hazard Ratio; CI, Confidence Interval; T2D, Type 2 Diabetes.

*Age 50 and over at start of follow-up

[†] Adjusted for age and cohort

[‡] Adjusted for age, cohort, smoking, alcohol, education, physical activity, oral contraceptive use, hormone therapy, age at menarche, number of pregnancies.

Figure 2. Life expectancy at 50 years old among women with late, normal and early menopause.



Abbreviations: HR, hazard ratio; LE life expectancy; T2D type 2 diabetes

*Results after adjusted for: age, cohort, education levels, alcohol, smoking, menarche, HT, physical activity, number of pregnancies and OC use.

**Late menopause group is the reference category.

389 **Table 3.** Differences of age at menopause categories on life expectancy.

390

Age at menopause categories	Difference in total LE		Difference in LE free of T2D		Difference in LE with T2D	
	Years	95% CI	Years	95% CI	Years	95% CI
Early vs. Late	-3.5	-6.6,-0.8	-4.6	-8.9,-0.9	1.1	-1.8,4.4
Normal vs. Late	-0.5	-2.1,1.3	-1.3	-4.3,0.8	0.8	-1.3,2.4
Early vs. Normal	-3.1	-5.1,-1.1	-3.3	-6.0,-0.6	0.2	-2.0,2.8

Abbreviations: LE life expectancy; T2D type 2 diabetes, CI confidence interval